Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 89, Issue 5, 2014, Pages 1038-1046

  Den, Robert B ^a   Feng, Felix Y ^b   Showalter, Timothy N ^c   Mishra, Mark V ^d   Trabulsi, Edouard J ^a   Lallas, Costas D ^a   Gomella, Leonard G ^a   Kelly, W Kevin ^a   Birbe, Ruth C ^a   McCue, Peter A ^a   Ghadessi, Mercedeh ^e   Yousefi, Kasra ^e   Davicioni, Elai ^e   Knudsen, Karen E ^a   Dicker, Adam P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^e GenomeDx Biosciences Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; GENES; OLIGONUCLEOTIDES; RADIOTHERAPY; REGRESSION ANALYSIS; RNA; UROLOGY;

COX REGRESSION ANALYSIS; HIGH-RISK PROSTATE CANCERS; MULTIVARIABLE ANALYSIS; POSTOPERATIVE RADIATION THERAPY; PROSTATE SPECIFIC ANTIGEN; RADICAL PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC CURVES; RECEIVER OPERATING CHARACTERISTICS;

PATHOLOGY;

OLIGONUCLEOTIDE; PARAFFIN; PROSTATE SPECIFIC ANTIGEN; RNA;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL FAILURE; CALIBRATION; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CLASSIFIER; CLINICAL ASSESSMENT TOOL; DISTANT METASTASIS; GENOMIC CLASSIFIER; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; AREA UNDER CURVE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; REGRESSION ANALYSIS; RNA, NEOPLASM; ROC CURVE; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 84904087751     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.04.052     Document Type: Article

References (32)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. G.P. Swanson, M.A. Hussey, and C.M. Tangen et al. Predominant treatment failure in postprostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794 J Clin Oncol 25 2007 2225 2229
3. R.K. Valicenti, I. Thompson, and P. Albertsen et al. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines Int J Radiat Oncol Biol Phys 86 2013 822 828
4. I.M. Thompson, C.M. Tangen, and J. Paradelo et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial J Urol 181 2009 956 962
5. I.M. Thompson, C.M. Tangen, and J. Paradelo et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial JAMA 296 2006 2329 2335
6. T. Wiegel, D. Bottke, and U. Steiner et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 2009 2924 2930
7. M. Bolla, H. van Poppel, and L. Collette et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911) Lancet 366 2012 572 578
8. B.J. Trock, M. Han, and S.J. Freedland et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy JAMA 299 2008 2760 2769
9. A.V. D'Amico, M.H. Chen, and L. Sun et al. Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death BJU Int 106 2010 1618 1622
10. N. Erho, A. Crisan, and I.A. Vergara et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy PLoS One 8 2013 e66855
11. R.J. Karnes, E.J. Bergstralh, and E. Davicioni et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population J Urol 190 2013 2047 2053
12. M.S. Pepe, Z. Feng, H. Janes, P.M. Bossuyt, and J.D. Potter Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design J Natl Cancer Inst 100 2008 1432 1438
13. L.M. McShane, D.G. Altman, and W. Sauerbrei et al. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting reccommendations for tumour MARKer prognostic studies (REMARK) Br J Cancer 93 2005 387 391
14. M.V. Mishra, E.D. Scher, and J. Andrel et al. Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse pathologic features: Comparative analysis of long-term outcomes Am J Clin Oncol 2013 Mar 26 [Epub ahead of print] http://dx.doi.org/10.1097/COC.0b013e318287bb6b
15. H.E. Lockstone Exon array data analysis using Affymetrix power tools and R statistical software Brief Bioinform 12 2011 634 644
16. S.R. Piccolo, Y. Sun, and J.D. Campbell et al. A single-sample microarray normalization method to facilitate personalized-medicine workflows Genomics 100 2012 337 344
17. M.R. Cooperberg, J.F. Hilton, and P.R. Carroll The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy Cancer 117 2011 5039 5046
18. A.J. Stephenson, P.T. Scardino, and J.A. Eastham et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J Clin Oncol 23 2008 7005 7012
19. R. Tibshirani The LASSO method for variable selection in the Cox model Stat Med 16 1997 385 395
20. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
21. P. Peduzzi, J. Concato, and A.R. Feinstein et al. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates J Clin Epidemiol 48 1995 1503 1510
22. R. Shinghal, C. Yemoto, and J.E. McNeal et al. Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. Prostate-specific antigen Urology 61 2003 380 385
23. I.M. Thompson, C.M. Tangen, and E.A. Klein Is there a standard of care for pathologic stage T3 prostate cancer? J Clin Oncol 27 2009 2898 2899
24. W.U. Shipley, D. Hunt, and H. Lukka et al. Initial report of RTOG 9601: A phase III trial in prostate cancer: Anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) improves freedom from progression and reduces the incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3, N0 disease, and elevated PSA levels (Abstr.) Int J Radiat Oncol 78 2010 S27
25. K. Fizazi, H.I. Scher, and A. Molina et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 2012 983 992
26. H.I. Scher, K. Fizazi, and F. Saad et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
27. J.S. De Bono, C.J. Logothetis, and A. Molina et al. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
28. P.G. Stock, P.F. Gores, and D.B. Kaufmann et al. Immunogenic potential of passenger leucocyte depleted murine islets in-vitro and in-vivo Horm Metab Res Suppl 25 1990 88 89
29. C. Parker, S. Nilsson, and D. Heinrich et al. Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 2013 213 223
30. P.W. Kantoff, C.S. Higano, and N.D. Shore et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
31. K. Badani, and D.J.S. Thompson et al. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: A report from the DECIDE study group Oncotarget 4 2013 600 609
32. P.L. Nguyen, X. Gu, and S.R. Lipsitz et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer J Clin Oncol 29 2011 1517 1524